Beijing Tiantan Valuation Multiples

Beijing Tiantan Overview

About Beijing Tiantan

Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.

Founded

1998

HQ

Employees

5.3K

Website

tiantanbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $921M

EBITDA: $339M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Beijing Tiantan Financials

Beijing Tiantan reported last 12-month revenue of $921M and EBITDA of $339M.

In the same LTM period, Beijing Tiantan generated $404M in gross profit, $339M in EBITDA, and $169M in net income.

Beijing Tiantan P&L

In the most recent fiscal year, Beijing Tiantan reported revenue of $904M and EBITDA of $331M.

Beijing Tiantan expects next 12-month revenue of XXX and NTM EBITDA of XXX

Beijing Tiantan Stock Performance

Beijing Tiantan has current market cap of $4B, and enterprise value of $4B.

Beijing Tiantan's stock price is $2.23.

Beijing Tiantan Valuation Multiples

Beijing Tiantan trades at 4.5x EV/Revenue multiple, and 12.2x EV/EBITDA.

Beijing Tiantan Financial Valuation Multiples

As of April 19, 2026, Beijing Tiantan has market cap of $4B and EV of $4B.

Equity research analysts estimate Beijing Tiantan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Beijing Tiantan has a P/E ratio of 26.0x.

Beijing Tiantan Margins & Growth Rates

Beijing Tiantan's revenue in the last 12 month grew by 11%.

Beijing Tiantan's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

Beijing Tiantan's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Beijing Tiantan's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Beijing Tiantan Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Beijing Tiantan M&A Activity

Beijing Tiantan acquired XXX companies to date.

Last acquisition by Beijing Tiantan was on XXXXXXXX, XXXXX. Beijing Tiantan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Beijing Tiantan Investment Activity

Beijing Tiantan invested in XXX companies to date.

Beijing Tiantan made its latest investment on XXXXXXXX, XXXXX. Beijing Tiantan invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).